Compare Organon & Co. Common Stock (OGN) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Ralph Lauren Corp — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Ralph Lauren Corp trades at $377.31 (market cap $22.27B). The key difference: Ralph Lauren Corp is far larger — about 6.2× Organon & Co. Common Stock's market cap, and Ralph Lauren Corp pays the higher dividend (1.07%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Ralph Lauren Corp for 84 Days on average.
| OGN | RL | |
|---|---|---|
Market Cap | $3.62B | $22.27B |
Volume | 2,892,999 | 320,311 |
Sector | Health | Consumer Cyclical |
52-Week High | $13.81 | $414.25 |
52-Week Low | $5.70 | $309.29 |
Typical Hold Time | 0 Days | 84 Days |
Enterprise Value | $11.04B | $23.33B |
Dividend Yield | 0.58% | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Ralph Lauren (RL) trades at $375.27, up 0.54% on the day, with a bullish technical outlook and strong fundamental performance. Recent quarters show consistent earnings beats, with Q2 2026 EPS of $4.59 exceeding the $4.32 estimate. Revenue growth is steady, reaching $7.08B in 2025, while profitability metrics like a 70.27% gross margin and 37.54% ROE highlight operational strength. The company maintains a solid balance sheet with $2.08B in cash and a declining debt-to-asset ratio of 16.21% in 2025.
The stock presents a favorable risk-reward profile, supported by a $456.67 analyst price target implying 22% upside. Key risks include reliance on luxury consumer spending and macroeconomic sensitivity. Positive sentiment is driven by expansion initiatives and dividend stability, with a $1.00 dividend declared for October 2026. Institutional confidence remains high, with 66.67% of analysts rating it a Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
